NASDAQ:MRSN Mersana Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.00 +0.09 (+1.83%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$4.85▼$5.2550-Day Range$2.84▼$5.0052-Week Range$2.68▼$14.80Volume5.26 million shsAverage Volume1.20 million shsMarket Capitalization$484.95 millionP/E RatioN/ADividend YieldN/APrice Target$21.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock Forecast (MarketRank)Overall MarketRank™2.40 out of 5 starsMedical Sector194th out of 1,417 stocksPharmaceutical Preparations Industry79th out of 675 stocksAnalyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.25, Mersana Therapeutics has a forecasted upside of 325.0% from its current price of $5.00.Amount of Analyst CoverageMersana Therapeutics has received no research coverage in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesMersana Therapeutics has received 235 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMersana Therapeutics has received 111 “underperform” votes. (Add your “underperform” vote.)Community SentimentMersana Therapeutics has received 67.92% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote “Outperform” if you believe MRSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have bought 31,636.15% more of their company's stock than they have sold. Specifically, they have bought $4,623,322.00 in company stock and sold $14,568.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Mersana Therapeutics is held by insiders.Percentage Held by Institutions92.74% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($2.13) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mersana Therapeutics (NASDAQ:MRSN)Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More MRSN Stock News HeadlinesJune 20, 2022 | finance.yahoo.comBeam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?June 5, 2022 | americanbankingnews.comInsider Buying: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Director Purchases $264,889.52 in StockJune 3, 2022 | benzinga.comMersana Therapeutics's Return On Capital Employed OverviewMay 23, 2022 | finance.yahoo.comInvestors in Mersana Therapeutics (NASDAQ:MRSN) from a year ago are still down 75%, even after 17% gain this past weekMay 19, 2022 | seekingalpha.comBain Capital's Andrew Hack buys shares worth ~$1.1M in Mersana TherapeuticsMay 19, 2022 | markets.businessinsider.comMersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer DrugMay 19, 2022 | seekingalpha.comMersana wins FDA’s Orphan Drug Designation for gastric cancer candidateMay 19, 2022 | nasdaq.comMersana Therapeutics: High on Strong Insider BuyingMay 19, 2022 | finance.yahoo.comMersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric CancerMay 9, 2022 | seekingalpha.comMersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial ResultsMay 2, 2022 | finance.yahoo.comMersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022April 23, 2022 | finance.yahoo.comWhat Type Of Shareholders Make Up Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Share Registry?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees169Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/25/2022Next Earnings (Estimated)8/05/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$21.25 High Stock Price Forecast$32.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+325.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.490010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-170.06 million Net Margins-8,826.73% Pretax Margin-8,826.73% Return on Equity-119.10% Return on Assets-78.07% Debt Debt-to-Equity Ratio0.18 Current Ratio4.28 Quick Ratio4.28 Sales & Book Value Annual Sales$40 thousand Price / Sales12,123.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book2.96Miscellaneous Outstanding Shares96,990,000Free Float91,850,000Market Cap$484.95 million OptionableNot Optionable Beta2.38 Mersana Therapeutics Frequently Asked Questions Should I buy or sell Mersana Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Mersana Therapeutics stock. View analyst ratings for Mersana Therapeutics or view top-rated stocks. What is Mersana Therapeutics' stock price forecast for 2022? 4 equities research analysts have issued 12 month price objectives for Mersana Therapeutics' stock. Their MRSN stock forecasts range from $16.00 to $32.00. On average, they expect Mersana Therapeutics' share price to reach $21.25 in the next twelve months. This suggests a possible upside of 325.0% from the stock's current price. View analysts' price targets for Mersana Therapeutics or view top-rated stocks among Wall Street analysts. How has Mersana Therapeutics' stock performed in 2022? Mersana Therapeutics' stock was trading at $6.22 on January 1st, 2022. Since then, MRSN stock has decreased by 19.6% and is now trading at $5.00. View the best growth stocks for 2022 here. Are investors shorting Mersana Therapeutics? Mersana Therapeutics saw a increase in short interest in May. As of May 31st, there was short interest totaling 5,870,000 shares, an increase of 26.5% from the May 15th total of 4,640,000 shares. Based on an average trading volume of 1,480,000 shares, the days-to-cover ratio is presently 4.0 days. View Mersana Therapeutics' Short Interest. When is Mersana Therapeutics' next earnings date? Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Mersana Therapeutics. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) posted its earnings results on Monday, May, 9th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.28. Mersana Therapeutics had a negative net margin of 8,826.73% and a negative trailing twelve-month return on equity of 119.10%. During the same quarter last year, the firm posted ($0.50) EPS. View Mersana Therapeutics' earnings history. Who are Mersana Therapeutics' key executives? Mersana Therapeutics' management team includes the following people: Ms. Anna Protopapas M.B.A., Pres, CEO & Director (Age 58, Pay $852.34k) (LinkedIn Profile)Mr. Brian C. DeSchuytner, Sr. VP & CFO (Age 44, Pay $570.49k)Dr. Timothy B. Lowinger Ph.D., Chief Science & Technology Officer (Age 58, Pay $598.29k) (LinkedIn Profile)Ms. Alejandra Veronica Carvajal J.D., SVP, Sec. & Chief Legal Officer (Age 48, Pay $511.29k)Dr. Tushar Misra Ph.D., SVP & Chief Manufacturing Officer (Age 62, Pay $485.89k)Mr. Mikhail Papisov Ph.D., Co-FounderMr. Ashish Mandelia, VP, Controller & Principal Accounting Officer (Age 48) (LinkedIn Profile)Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. CommunicationsMs. Carla Poulson, Chief People OfficerMr. Chuck Miller, Sr. VP of Regulatory Affairs What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO? 3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Mersana Therapeutics' key competitors? Some companies that are related to Mersana Therapeutics include ChemoCentryx (CCXI), Arcus Biosciences (RCUS), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Xenon Pharmaceuticals (XENE), Emergent BioSolutions (EBS), Lyell Immunopharma (LYEL), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), Amphastar Pharmaceuticals (AMPH), Dynavax Technologies (DVAX), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND) and Cryoport (CYRX). View all of MRSN's competitors. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS). When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.15%), Bellevue Group AG (4.08%), Rock Springs Capital Management LP (3.87%), Vanguard Group Inc. (3.54%), Artal Group S.A. (2.64%) and Candriam Luxembourg S.C.A. (1.90%). Company insiders that own Mersana Therapeutics stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger. View institutional ownership trends for Mersana Therapeutics. Which institutional investors are selling Mersana Therapeutics stock? MRSN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Citigroup Inc., Bellevue Group AG, Candriam Luxembourg S.C.A., Vanguard Group Inc., UBS Group AG, and Allianz Asset Management GmbH. Company insiders that have sold Mersana Therapeutics company stock in the last two years include Alejandra Carvajal, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, and Timothy B Lowinger. View insider buying and selling activity for Mersana Therapeutics or view top insider-selling stocks. Which institutional investors are buying Mersana Therapeutics stock? MRSN stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Artal Group S.A., Decheng Capital Management III Cayman LLC, Renaissance Technologies LLC, Federated Hermes Inc., Rock Springs Capital Management LP, Goldman Sachs Group Inc., and Pinz Capital Management LP. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva. View insider buying and selling activity for Mersana Therapeutics or or view top insider-buying stocks. How do I buy shares of Mersana Therapeutics? Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $5.00. How much money does Mersana Therapeutics make? Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $484.95 million and generates $40 thousand in revenue each year. The company earns $-170.06 million in net income (profit) each year or ($2.490010) on an earnings per share basis. How many employees does Mersana Therapeutics have? Mersana Therapeutics employs 169 workers across the globe. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for Mersana Therapeutics is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at [email protected]. This page (NASDAQ:MRSN) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here